Qureight raises $20m in Series B funding led by Molten Ventures to scale clinical trial platform
Molten Ventures led the Series B round to support the creation of an artificial intelligence imaging lab.
≈ £15.0M at $1 = £0.7481 on 29 Jul 2026
Cambridge-based Qureight builds artificial intelligence tools to support pharmaceutical companies running clinical trials for respiratory and cardiovascular diseases.
Qureight has secured $20m in a Series B funding round led by Molten Ventures to expand its artificial intelligence imaging platform. The transaction follows previous support from backers including Hargreave Hale AIM VCT and XTX Ventures.
The capital will enable the Cambridge business to establish an in-house imaging laboratory and broaden its trial focus into conditions such as asthma and pulmonary hypertension. Co-founded in 2018 by clinicians, the firm provides digital tooling to accelerate image analysis for pharmaceutical drug developers.
From the founder
"There was an area to go and help these pharma companies do better clinical trials, and so that’s how the company started"
Muhunthan Thillai
Co-founder and CEO at Qureight
Investor perspective
"Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team’s rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation. We look forward to working with Muhunthan and the team as they deliver on this vision."
Inga Deakin
Partner, Molten
Use of funds
- 01Grow the team
- 02Build out infrastructure
- 03Expand into international markets
